WO2003095423A1 - A process for the preparation of modafinil - Google Patents

A process for the preparation of modafinil Download PDF

Info

Publication number
WO2003095423A1
WO2003095423A1 PCT/EP2003/004229 EP0304229W WO03095423A1 WO 2003095423 A1 WO2003095423 A1 WO 2003095423A1 EP 0304229 W EP0304229 W EP 0304229W WO 03095423 A1 WO03095423 A1 WO 03095423A1
Authority
WO
WIPO (PCT)
Prior art keywords
diphenylmethyl
sulfinyl
sodium
acetate
modafinil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/004229
Other languages
English (en)
French (fr)
Inventor
Graziano Castaldi
Vittorio Lucchini
Antonio Tarquini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dipharma Francis SRL
Dipharma SpA
Original Assignee
Dinamite Dipharma SpA
Dipharma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/513,881 priority Critical patent/US7057068B2/en
Priority to EA200401235A priority patent/EA007327B1/ru
Priority to KR10-2004-7018040A priority patent/KR20040108789A/ko
Priority to AU2003227668A priority patent/AU2003227668A1/en
Priority to DE60314410T priority patent/DE60314410T2/de
Priority to EP03725083A priority patent/EP1503983B1/en
Priority to JP2004503444A priority patent/JP4351626B2/ja
Priority to MXPA04011141A priority patent/MXPA04011141A/es
Application filed by Dinamite Dipharma SpA, Dipharma SpA filed Critical Dinamite Dipharma SpA
Priority to DK03725083T priority patent/DK1503983T3/da
Priority to CA002485428A priority patent/CA2485428A1/en
Publication of WO2003095423A1 publication Critical patent/WO2003095423A1/en
Priority to IL16512104A priority patent/IL165121A0/xx
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00Preparation of sulfones; Preparation of sulfoxides
    • C07C315/02Preparation of sulfones; Preparation of sulfoxides by formation of sulfone or sulfoxide groups by oxidation of sulfides, or by formation of sulfone groups by oxidation of sulfoxides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton

Definitions

  • the present invention relates psychostimulants, in particular to a novel process for the preparation of 2-[(diphenylmethyl)sulfinyl]acetamide (1), also known as modafinil.
  • Modafinil (1) is an oti-adrenergic agonist having psychostimulant activity, used for the treatment of idiopathic narcoplepsy .
  • the process involves the use of dimethyl sulfate, which is a cancerogenic reagent.
  • optically active 2-[2-[(diphenylmethyl)sulfinyl]acetic acid (9) is converted to the methyl ester (10) with NaHC0 3 and dimethyl sulfate, then is subjected to a transamidation reaction with ammonia.
  • WO 02/10125 discloses a method for the preparation of modafinil and its polymorphs by oxidation of 2-[(diphenylmethyl)sulfenyl]acetamide (3) with hydrogen peroxide in the presence of a mineral acid and of an alcohol or a phase transfer catalyst; this overcomes the problem of overoxidation.
  • a recrystallization step is necessary to obtain the final product with pharmaceutically acceptable purity. It would therefore be advantageous to provide a method which not only prevents the sulfone formation, but also directly affords modafinil with a pharmaceutically acceptable purity.
  • the present invention relates to a process for the preparation of 2-[(diphenylmethyl)sulfinyl ]acetamide (1)
  • the reaction is carried out in the presence of bases such as alkali and alkaline-earth oxides and hydroxides, alkali and alkaline- earth carbonates and bicarbonates, alkoxides and alkoxides in alcoholic solution, in amounts ranging from 1 to 5 equivalents, preferably from 1.1 to 2 equivalents.
  • the solvent can be selected from toluene, chlorinated solvents, preferably dichloromethane, esters, preferably ethyl acetate, ethers, preferably diethyl ether, tetrahydrofuran, dipolar aprotic solvents, preferably dimethylformamide, cyclohexane, alcohols, preferably methanol, ethanol and isopropanol, ketones, preferably acetone, or a mixture thereof, in amounts ranging from 1 to 10 volumes, preferably from 3 to 6 volumes.
  • chlorinated solvents preferably dichloromethane
  • esters preferably ethyl acetate, ethers, preferably diethyl ether, tetrahydrofuran
  • dipolar aprotic solvents preferably dimethylformamide, cyclohexane
  • alcohols preferably methanol, ethanol and isopropanol
  • ketones preferably acetone, or a mixture thereof, in amounts ranging from 1 to
  • the ester of formula (15) is not isolated, but is directly hydrolysed to give the sodium salt (11) in the presence of aqueous solutions of oxides, hydroxides, alkali and alkaline- earth carbonates and bicarbonates in amounts ranging from 1 to 5 equivalents, preferably from 1.1 to 2 equivalents.
  • oxidation of salt (11) is performed distilling off the water-solvent mixture, taking up the residue with water and treating with a sodium hypochlorite aqueous solution at concentrations ranging from 2 to 30%, preferably from 5 to 15%, in amounts ranging from 1 to 5 equivalents, preferably from 1.1 to 2 equivalents.
  • the reaction is carried out at temperatures ranging from -10 to 80°C, preferably from 10 to 60°C.
  • Transformation of acid (9) into modafinil is carried out by treatment with condensing agents and ammonia.
  • the conventional method of chemical activation of the carboxylic group i.e. the transformation of the acid into the corresponding chloride, is not compatible with the sulfoxide group (see Oae "Organic Chemistry of Sulfur” Plenum Press N.Y. 1977 page 406), which would be reduced to sulfide under these conditions.
  • the condensing agent is preferably selected from N,N'- carbonyldiimidazole, N,N'-carbonylditriazole, dicyclohexylcarbodiimide, preferably N,N'-carbonyldiimidazole, in amounts ranging from 1 to 5 equivalents, preferably from 1.1 to 2.0 equivalents.
  • the reaction solvent is selected from toluene, chlorinated solvents, preferably dichloromethane, esters, preferably ethyl acetate, ethers, preferably diethyl ether, tetrahydrofuran, dipolar aprotic solvents, preferably dimethylformamide, cyclohexane, ketones, preferably acetone, in amounts ranging from 1 to 10 volumes, preferably from 3 to 6 volumes.
  • the solvent is dichloromethane.
  • the reaction is carried out at a temperature ranging from -10 to 50°C, preferably from 0 to 20°C.
  • the reaction proceeds through a reactive intermediate which is not isolated and which is reacted with gas ammonia at a temperature ranging from -10 to 30°C, preferably from 0 to 10°C, to yield modafinil.
  • Ammonia can be used either in gaseous phase or in aqueous solution, at concentrations ranging from 5 to 30% and in amounts ranging from 1 to 5 equivalents, preferably from 1.2 to 2 equivalents.
  • the product is obtained in yields of 70 ⁇ 75% with respect to [(diphenylmethyl)sulfinyl]acetic acid and with % HPLC purity > 99.5%.
  • the mass is cooled to 40 ⁇ 45°C inner temperature and 360 ml of a 5% sodium hypochlorite aqueous solution (0.24 mols) are added, in about 2 hours. 15' After the end of the addition, the mass is cooled to 20 ⁇ 25°C inner temperature, added with 180 ml of toluene and acidified with 88 ml of 50% sulfuric acid, keeping pH at 2; the precipitated product is filtered, washed with water to neutrality, then squeezed and dried in oven under vacuum at a temperature of 55 ⁇ 60°C, thereby obtaining 44 g (0.16 mols) of 2- [(di ⁇ henylmethyl)sulfmyl] acetic acid (9) (yield: 73%).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
PCT/EP2003/004229 2002-05-10 2003-04-23 A process for the preparation of modafinil Ceased WO2003095423A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2004503444A JP4351626B2 (ja) 2002-05-10 2003-04-23 モダフィニルの製造方法
KR10-2004-7018040A KR20040108789A (ko) 2002-05-10 2003-04-23 모다피닐의 제조방법
AU2003227668A AU2003227668A1 (en) 2002-05-10 2003-04-23 A process for the preparation of modafinil
DE60314410T DE60314410T2 (de) 2002-05-10 2003-04-23 Verfahren zur herstellung von modafinil
EP03725083A EP1503983B1 (en) 2002-05-10 2003-04-23 A process for the preparation of modafinil
US10/513,881 US7057068B2 (en) 2002-05-10 2003-04-23 Process for the preparation of modafinil
CA002485428A CA2485428A1 (en) 2002-05-10 2003-04-23 A process for the preparation of modafinil
MXPA04011141A MXPA04011141A (es) 2002-05-10 2003-04-23 Procedimiento para la preparacion de modafinil.
DK03725083T DK1503983T3 (da) 2002-05-10 2003-04-23 Fremgangsmåde til fremstilling af modafinil
EA200401235A EA007327B1 (ru) 2002-05-10 2003-04-23 Способ получения модафинила
IL16512104A IL165121A0 (en) 2002-05-10 2004-11-09 A process for the preparation of modafinil

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2002A000991 2002-05-10
IT2002MI000991A ITMI20020991A1 (it) 2002-05-10 2002-05-10 Procedimento per la sintesi del modafinil

Publications (1)

Publication Number Publication Date
WO2003095423A1 true WO2003095423A1 (en) 2003-11-20

Family

ID=11449867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/004229 Ceased WO2003095423A1 (en) 2002-05-10 2003-04-23 A process for the preparation of modafinil

Country Status (17)

Country Link
US (1) US7057068B2 (https=)
EP (1) EP1503983B1 (https=)
JP (1) JP4351626B2 (https=)
KR (1) KR20040108789A (https=)
AT (1) ATE364593T1 (https=)
AU (1) AU2003227668A1 (https=)
CA (1) CA2485428A1 (https=)
DE (1) DE60314410T2 (https=)
DK (1) DK1503983T3 (https=)
EA (1) EA007327B1 (https=)
ES (1) ES2286429T3 (https=)
IL (1) IL165121A0 (https=)
IT (1) ITMI20020991A1 (https=)
MX (1) MXPA04011141A (https=)
PL (1) PL371679A1 (https=)
PT (1) PT1503983E (https=)
WO (1) WO2003095423A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1777295A3 (en) * 2005-10-18 2007-06-20 Dipharma S.p.A. A process for the preparation of (-) modafinil
US8193386B2 (en) 2007-11-05 2012-06-05 Dipharma Francis S.R.L. Crystalline form of (S)-1-phenylethylammonium (R)-diphenylmethanesulphinyl-acetate
CN114044730A (zh) * 2021-11-26 2022-02-15 台州学院 一种亚砜类化合物的合成方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2003529A3 (cs) 2000-07-27 2003-09-17 Teva Pharmaceutical Industries Ltd. Krystalický a čistý modafinil a postup jeho přípravy
US20070293702A1 (en) * 2006-02-21 2007-12-20 Viviana Braude Novel crystalline forms of armodafinil and preparation thereof
WO2007103221A2 (en) * 2006-03-01 2007-09-13 Teva Pharmaceutical Industries Ltd. An improved process for the preparation of armodafinil
KR20090031618A (ko) * 2006-07-12 2009-03-26 엘란 코포레이션, 피엘씨 나노입자형 모다피닐 제제
WO2009025791A2 (en) * 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Purification of armodafinil
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE221261C (https=) *
US4062973A (en) * 1975-10-16 1977-12-13 Boehringer Ingelheim Gmbh Sulfur-containing derivatives of cyclohexylphenyl-ethane
US4177290A (en) * 1977-03-31 1979-12-04 Laboratoire L. Lafon Acetamide derivatives
US4964893A (en) * 1986-04-17 1990-10-23 Monsanto Company Benzhydryl compounds as herbicide antidotes
WO2002010125A1 (en) * 2000-07-27 2002-02-07 Teva Pharmaceutical Industries Ltd. Crystalline and pure modafinil, and process of preparing the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE221261C (https=) *
US4062973A (en) * 1975-10-16 1977-12-13 Boehringer Ingelheim Gmbh Sulfur-containing derivatives of cyclohexylphenyl-ethane
US4177290A (en) * 1977-03-31 1979-12-04 Laboratoire L. Lafon Acetamide derivatives
US4964893A (en) * 1986-04-17 1990-10-23 Monsanto Company Benzhydryl compounds as herbicide antidotes
WO2002010125A1 (en) * 2000-07-27 2002-02-07 Teva Pharmaceutical Industries Ltd. Crystalline and pure modafinil, and process of preparing the same

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1777295A3 (en) * 2005-10-18 2007-06-20 Dipharma S.p.A. A process for the preparation of (-) modafinil
US8193386B2 (en) 2007-11-05 2012-06-05 Dipharma Francis S.R.L. Crystalline form of (S)-1-phenylethylammonium (R)-diphenylmethanesulphinyl-acetate
CN114044730A (zh) * 2021-11-26 2022-02-15 台州学院 一种亚砜类化合物的合成方法
CN114044730B (zh) * 2021-11-26 2024-04-23 台州学院 一种亚砜类化合物的合成方法

Also Published As

Publication number Publication date
JP4351626B2 (ja) 2009-10-28
ES2286429T3 (es) 2007-12-01
JP2005525420A (ja) 2005-08-25
US7057068B2 (en) 2006-06-06
IL165121A0 (en) 2005-12-18
EA007327B1 (ru) 2006-08-25
MXPA04011141A (es) 2005-07-01
EP1503983A1 (en) 2005-02-09
AU2003227668A1 (en) 2003-11-11
DE60314410D1 (de) 2007-07-26
DE60314410T2 (de) 2008-02-14
DK1503983T3 (da) 2007-09-10
US20050154063A1 (en) 2005-07-14
CA2485428A1 (en) 2003-11-20
EA200401235A1 (ru) 2005-06-30
PT1503983E (pt) 2007-07-31
ATE364593T1 (de) 2007-07-15
KR20040108789A (ko) 2004-12-24
PL371679A1 (en) 2005-06-27
EP1503983B1 (en) 2007-06-13
ITMI20020991A0 (it) 2002-05-10
ITMI20020991A1 (it) 2003-11-10

Similar Documents

Publication Publication Date Title
CN100379721C (zh) 亚磺酰乙酰胺的制备
EP1503983B1 (en) A process for the preparation of modafinil
KR0176010B1 (ko) 1-아미노-1,2,3-트리아졸의 제법
RU2436773C2 (ru) Способ получения натриевой соли 1-[[[(r)-m-[(е)-2-(7-хлор-2-хинолил)винил]-альфа-[о-(1-гидрокси-1-метилэтил)фенетил]бензил]тио]метил]циклопропануксусной кислоты
EP1907396B1 (fr) Procede de preparation de la 4 -amino-4'-demethyl-4-desoxypodophyllotoxine
WO2002053518A2 (en) HALOGENATED-α,β-UNSATURATED-β-(SUBSTITUTED-AMINO) CARBOXYLATE ESTERS
EP1474386B1 (en) Process for the preparation of 1-(mercaptomethyl)-cyclopropaneacetic acid
CN110563670B (zh) 一种含硫哌嗪衍生物及其应用
CN111039838A (zh) 一种3-乙酰巯基-2-甲基丙酸的制备方法
KR20110054670A (ko) 2-시아노-3-히드록시-엔-[(4-트리플루오로메틸)페닐]부트-2-엔아미드의 제조방법
WO2008115912A1 (en) Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid
AU2006274461A1 (en) Process for the production of bicalutamide
WO2025022637A1 (ja) カルボン酸エステル誘導体の脱水縮合をともなう環化反応による環化生成物の製造方法、および1,3,4-置換-ピラゾール-5-カルボン酸エステル類の製造方法
KR100518933B1 (ko) 옥사졸린-아제티디논 유도체의 정제방법
JP3581721B2 (ja) N−置換−3−ヨードプロピオール酸アミドおよびその合成中間体の製造方法
JPS60226860A (ja) ベンズオキサゾリル−及びベンズチアゾリルオキシフエノキシプロピオン酸誘導体の製造法
KR20070114343A (ko) 비칼루타미드의 제조 방법
EP1777221A1 (en) Process for the preparation of 5-cyanophthalide starting from 5-carboxyphthalide
JPS6228780B2 (https=)
CA2562354A1 (fr) Procede de synthese et intermediaires de benzoxathiepines
KR20020073980A (ko) 디벤조티에핀 유도체의 신규 제조방법
JP2003128644A (ja) ベンジル(ジフルオロメチル)スルフィドの製造方法
JP2003342267A (ja) エポキシブタン酸エステル類の製造方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 200401235

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 3396/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 10513881

Country of ref document: US

Ref document number: 1020047018040

Country of ref document: KR

Ref document number: 2004503444

Country of ref document: JP

Ref document number: 2485428

Country of ref document: CA

Ref document number: PA/a/2004/011141

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003725083

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020047018040

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003725083

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003725083

Country of ref document: EP